Skip to main content

Table 3 Multivariable Fine and Gray models of time to events

From: Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients

  Virologic Failure or Other Discontinuation Virologic Failure Discontinuation due to Virologic Failure Other Discontinuation Virologic Suppression
aHR (95% CI) p aHR (95% CI) p aHR (95% CI) p aHR (95% CI) p aHR (95% CI) p
DRV/RIT 0.76 (0.56,1.03) 0.08 0.50 (0.28,0.91) 0.02 0.00 (0.00,0.00) <.0001 0.93 (0.65,1.33) 0.68 0.99 (0.82,1.21) 0.96
FTC/TEN 1.02 (0.86,1.21) 0.84 1.30 (0.99,1.70) 0.06 1.41 (0.87,2.28) 0.16 0.87 (0.70,1.08) 0.20 0.99 (0.87,1.12) 0.82
Age (per 10y) 0.89 (0.83,0.95) <.001 1.02 (0.91,1.15) 0.70 0.89 (0.73,1.09) 0.27 0.86 (0.79,0.94) <.001 1.04 (0.98,1.10) 0.17
Gender & MSM
 Female Ref.   Ref.   Ref.   Ref.   Ref.  
 MSM 0.68 (0.55,0.84) <.001 0.73 (0.51,1.03) 0.08 0.46 (0.24,0.89) 0.02 0.79 (0.61,1.03) 0.08 1.20 (1.00,1.45) 0.05
 Male, not MSM 0.72 (0.59,0.88) <.01 0.90 (0.64,1.25) 0.51 0.70 (0.42,1.17) 0.17 0.76 (0.59,0.98) 0.03 1.06 (0.87,1.28) 0.57
 Missing 0.74 (0.56,0.98) 0.03 0.80 (0.47,1.35) 0.40 0.64 (0.27,1.55) 0.33 0.83 (0.60,1.15) 0.26 1.13 (0.90,1.42) 0.31
Race
White Ref.   Ref.   Ref.   Ref.   Ref.  
Black 0.89 (0.64,1.23) 0.47 1.41 (0.88,2.26) 0.15 1.18 (0.47,2.95) 0.72 0.64 (0.40,1.04) 0.07 1.16 (0.88,1.54) 0.29
Aboriginal Peoples 1.39 (1.05,1.85) 0.02 1.14 (0.72,1.82) 0.57 1.46 (0.71,2.99) 0.30 1.32 (0.91,1.89) 0.14 0.68 (0.51,0.92) 0.01
Other 0.89 (0.67,1.18) 0.42 1.04 (0.68,1.59) 0.86 0.79 (0.36,1.75) 0.56 0.82 (0.56,1.19) 0.29 1.15 (0.94,1.40) 0.17
Missing 1.17 (0.98,1.39) 0.08 0.75 (0.55,1.01) 0.06 0.70 (0.43,1.14) 0.15 1.38 (1.12,1.72) <.01 0.93 (0.80,1.08) 0.35
IDU
 No Ref.   Ref.   Ref.   Ref.   Ref.  
 Yes 1.68 (1.39,2.02) <.0001 1.46 (1.05,2.04) 0.03 1.64 (0.92,2.94) 0.09 1.50 (1.20,1.88) <.001 0.69 (0.58,0.82) <.0001
 Missing 1.11 (0.83,1.49) 0.48 1.16 (0.68,1.96) 0.58 1.10 (0.41,2.93) 0.85 1.04 (0.74,1.45) 0.83 0.91 (0.72,1.14) 0.40
Province
 BC Ref.   Ref.   Ref.   Ref.   Ref.  
 ON 0.95 (0.77,1.16) 0.60 1.11 (0.81,1.54) 0.52 0.67 (0.34,1.31) 0.24 0.90 (0.69,1.17) 0.44 0.97 (0.82,1.15) 0.73
 QC 0.82 (0.66,1.02) 0.08 1.26 (0.88,1.80) 0.21 1.03 (0.51,2.08) 0.93 0.68 (0.51,0.90) <.01 1.02 (0.86,1.21) 0.83
Baseline CD4 (per 100)
  < 200 Ref.   Ref.   Ref.   Ref.   Ref.  
 200–349 0.83 (0.71,0.96) 0.01 0.93 (0.73,1.20) 0.58 1.16 (0.76,1.77) 0.48 0.84 (0.69,1.02) 0.08 1.18 (1.04,1.33) <.01
 350–499 0.80 (0.63,1.01) 0.06 0.52 (0.33,0.84) <.01 0.60 (0.23,1.56) 0.29 1.00 (0.76,1.31) 0.99 1.35 (1.14,1.61) <.001
  ≥ 500 1.07 (0.80,1.45) 0.64 0.79 (0.44,1.42) 0.44 0.95 (0.33,2.69) 0.92 1.22 (0.87,1.71) 0.25 1.36 (1.08,1.71) <.01
 Baseline VL ≥ 100,000 1.20 (1.05,1.38) <.01 1.74 (1.38,2.20) <.0001 2.27 (1.49,3.48) <.001 0.95 (0.80,1.13) 0.57 0.61 (0.55,0.68) <.0001
Calendar Year
 2003–2006 Ref.   Ref.   Ref.   Ref.   Ref.  
 2007–2009 0.96 (0.79,1.17) 0.69 0.68 (0.50,0.92) 0.01 0.41 (0.24,0.71) <.01 1.11 (0.87,1.42) 0.39 0.96 (0.82,1.12) 0.58
 2010–2012 1.12 (0.88,1.42) 0.35 0.88 (0.61,1.28) 0.50 0.64 (0.33,1.24) 0.19 1.03 (0.77,1.38) 0.84 0.67 (0.56,0.81) <.0001
  1. AHR adjusted hazard ratio, DRV/r darunavir/ritonavir, ATZ/r atazanavir/ritonavir, FTC emtricitabine, TDF tenofovir, NRTI nucleoside reverse transcriptase inhibitor, MSM men who have sex with men, VL viral load